Overview
SCB-313 Preclinical Data Published in Scientific Reports
2017-08-21
–         Preclinical data for SCB-313, a recombinant human TRAIL-Trimer fusion protein, published in Scientific Reports
–         SCB-313 demonstrated superior antitumor activity compared to native TRAIL and dimeric agonist
 
CHENGDU, CHINA – 21 August 2017 – Clover Biopharmaceuticals, a biotechnology company focused on developing novel and transformative biologic therapies for oncology and autoimmune diseases, today announced the publication of preclinical data on SCB-313 (recombinant human TRAIL-Trimer fusion protein) in Scientific Reports.  
 
Publication details are as follows:
Title: “Improvement of Pharmacokinetic Profile of TRAIL via Trimer-Tag Enhances its Antitumor Activity in vivo
Authors: Haipeng Liu, Danmei Su, Jinlong Zhang, Shuaishuai Ge, Youwei Li, Fei Wang, Michel Gravel, Anne Roulston, Qin Song, Wei Xu, Joshua G. Liang, Gordon Shore, Xiaodong Wang, Peng Liang
Publication: Scientific Reports 7 (1):8953. DOI: 10.1038/s41598-017-09518-1
Available Online: www.nature.com/articles/s41598-017-09518-1
 
“We are delighted to have our research on SCB-313 peer-reviewed and published in Scientific Reports, marking the first time we have publicly unveiled details of our novel and proprietary Trimer-Tag© technology platform,” said Dr. Peng Liang, co-founder, Chairman and President. “TRAIL has long been a promising but elusive target in cancer therapy, with prior native TRAIL and agonist antibody approaches being flawed. SCB-313 overcomes these issues by exhibiting a markedly different pharmacokinetic profile and superior antitumor activity in head-to-head preclinical testing.”
 
“This is a timely publication for Clover, with SCB-313 expected to enter human clinical testing over the coming months,” said Joshua Liang, Chief Strategy Officer. “As the only fully-human trimeric TRAIL fusion protein currently in development, we hope that SCB-313 can provide clinical validation of Trimer-Tag© technology platform and TRAIL as a target in cancer therapy for the benefit of many cancer patients.”
 
About Clover Biopharmaceuticals
Clover Biopharmaceuticals is a global, research-based biotechnology company focused on discovering, developing and commercializing transformative biologic therapies, with a focus on oncology and autoimmune diseases. Clover is utilizing its proprietary Trimer-Tag© technology platform to develop novel biologics targeting trimerization-dependent pathways. Additionally, Clover is leveraging its in-house biomanufacturing capabilities to develop select biosimilars. For more information, please visit our website: www.cloverbiopharma.com.

上一篇:Clover's TNF Receptor Detection Methodology Published in Scientific Reports
下一篇:Clover Held its 2017 Board Meeting in Chengdu